Posted by Michael Wonder on 11 Dec 2016
ARCA Biopharma receives FDA fast track designation for Gencaro atrial fibrillation development in a genetically targeted heart failure population
13 April 2015 - ARCA Biopharma today announced that the U.S. FDA has designated as a fast track development program the investigation of Gencaro for the prevention of atrial fibrillation/atrial flutter in a genetically modified heart failure population (heart failure patients with reduced left ventricular ejection fraction).
Gencaro is the Company’s investigational, pharmacologically unique beta-blocker and mild vasodilator.
